Melissa K Accordino1, Jason D Wright2, Sowmya Vasan2, Alfred I Neugut2, Ana Tergas2, Jim C Hu2, Dawn L Hershman2, Melissa K Accordino1, Jason D Wright2, Sowmya Vasan2, Alfred I Neugut2, Ana Tergas2, Jim C Hu2, Dawn L Hershman2. 1. Columbia University College of Physicians and Surgeons; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons; Mailman School of Public Health, Columbia University; and Weill Cornell Medical College, New York, NY Mkg2134@cumc.columbia.edu. 2. Columbia University College of Physicians and Surgeons; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons; Mailman School of Public Health, Columbia University; and Weill Cornell Medical College, New York, NY.
Abstract
PURPOSE: There is substantial variability in the frequency of serum tumor marker testing in patients with advanced solid tumors. We performed a retrospective analysis to evaluate the frequency of serum tumor marker use. METHODS: Patients with a diagnosis of advanced cancer with outpatient visits between July 1, 2013, and June 30, 2014, at a single center were included. Tumor and stage were determined by International Classification of Diseases, Ninth Revision codes and confirmed with tumor registry and medical record review. For each patient, we recorded the dates of each of the following tumor markers: a-fetoprotein, CA-125, CA 15-3, CA 19-9, CA 27-29, and carcinoembryonic antigen. We evaluated the number of tests per patient over 12 months and the maximum number of tests per patient per month. RESULTS: We included 928 patients in the analysis. The mean number of any individual test per patient was seven tests, and the maximum number was 35 tests; the mean number of total tests per patient was 12 tests, and the maximum number was 70 tests; 16.3% of patients had more than 12 individual tests per year. In a 1-month span, 34.3% of patients had more than one individual test. CA 19-9 and carcinoembryonic antigen were the most commonly overused tests. CONCLUSION: We found a high rate of serum tumor marker testing use in patients with advanced solid tumors. Given the increasing costs of cancer care, efforts should be made to determine the benefit of serum tumor markers in the follow-up care of patients with advanced solid tumors.
PURPOSE: There is substantial variability in the frequency of serum tumor marker testing in patients with advanced solid tumors. We performed a retrospective analysis to evaluate the frequency of serum tumor marker use. METHODS:Patients with a diagnosis of advanced cancer with outpatient visits between July 1, 2013, and June 30, 2014, at a single center were included. Tumor and stage were determined by International Classification of Diseases, Ninth Revision codes and confirmed with tumor registry and medical record review. For each patient, we recorded the dates of each of the following tumor markers: a-fetoprotein, CA-125, CA 15-3, CA 19-9, CA 27-29, and carcinoembryonic antigen. We evaluated the number of tests per patient over 12 months and the maximum number of tests per patient per month. RESULTS: We included 928 patients in the analysis. The mean number of any individual test per patient was seven tests, and the maximum number was 35 tests; the mean number of total tests per patient was 12 tests, and the maximum number was 70 tests; 16.3% of patients had more than 12 individual tests per year. In a 1-month span, 34.3% of patients had more than one individual test. CA 19-9 and carcinoembryonic antigen were the most commonly overused tests. CONCLUSION: We found a high rate of serum tumor marker testing use in patients with advanced solid tumors. Given the increasing costs of cancer care, efforts should be made to determine the benefit of serum tumor markers in the follow-up care of patients with advanced solid tumors.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Donna L Johnston; Todd A Alonzo; Robert B Gerbing; Beverly J Lange; William G Woods Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Francisco Rodríguez-Moranta; Joan Saló; Angels Arcusa; Jaume Boadas; Virgínia Piñol; Xavier Bessa; Eduard Batiste-Alentorn; Antonio M Lacy; Salvadora Delgado; Joan Maurel; Josep M Piqué; Antoni Castells Journal: J Clin Oncol Date: 2005-12-19 Impact factor: 44.544
Authors: R C Bast; P Ravdin; D F Hayes; S Bates; H Fritsche; J M Jessup; N Kemeny; G Y Locker; R G Mennel; M R Somerfield Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani Journal: Am J Gastroenterol Date: 2006-03 Impact factor: 10.864
Authors: Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Grace C Hillyer; Jim C Hu; Dawn L Hershman Journal: J Clin Oncol Date: 2016-05-09 Impact factor: 44.544